The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
BrainStorm Cell Therapeutics Granted US Patent for Autologous Stem Cell Technology
Mar. 24, 2014 08:15AM PST
Life Science Investing NewsBrainStorm Cell Therapeutics (OTCQB:BCLI) was granted a key patent for its autologous stem cell technology by the U.S. Patent and Trademark Office. Patent No. 8,663,987 covers the Company’s proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
BrainStorm Cell Therapeutics (OTCQB:BCLI) was granted a key patent for its autologous stem cell technology by the U.S. Patent and Trademark Office. Patent No. 8,663,987 covers the Company’s proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
As quoted in the press release:
Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn™ stem cell therapy, which was developed with these cells.
Click here to read the BrainStorm Cell Therapeutics (OTCQB:BCLI) press release
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.